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Birgit Weinberger* , Michael Keller and Beatrix Grubeck-LoebensteinAbstract: Many currently used vaccines are less immunogenic in the elderly compared to young adults. The impact
of latent infection with Cytomegalovirus (CMV) on vaccine-induced antibody responses has been discussed
controversially. We have demonstrated that recall responses to diphtheria vaccination are frequently insufficient in elderly
persons and that antibody concentrations decline substantially within 5 years. In the current study we show that within a
cohort of healthy elderly (n = 87; median age 71 years, range 66–92) antibody responses to a booster vaccination against
diphtheria do not differ between CMV-negative and CMV-positive individuals 4 weeks after vaccination.. However, the
goal of diphtheria-vaccination is long-term protection and this is achieved by circulating anti-toxin antibodies. Diphtheria-
specific antibody concentrations decline faster in CMV-positive compared to CMV-negative older adults leading to
an increased proportion of persons without protective antibody concentrations 5 years after booster vaccination
and endangering long-term protection. This finding could be relevant for vaccination schedules.
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immune system, collectively termed immunosenescence,
which contribute to increased incidence and severity of
infection [1] and to decreased immunogenicity and effi-
cacy of vaccination [2, 3]. One hallmark of immunose-
nescence is the involution of the thymus, i.e. the gradual
replacement of functional thymic tissue by fat [4], lead-
ing to a severely decreased output of newly generated
naïve T cells and as a consequence to the loss of naïve T
cells in lymphoid organs and in the periphery [5, 6].
Concomitantly, highly differentiated effector T cells ac-
cumulate resulting in alterations of the cytokine profile
and in decreased diversity of the T cell repertoire [7].
Several studies have demonstrated that latent infection
with the human β-herpesvirus Cytomegalovirus (CMV),
which is prevalent without clinical symptoms in 60–
100% of the adult population, aggravates age-related
changes of the T cell compartment [6, 8, 9] and is part
of the “immune risk phenotype”, which predicts 2-year* Correspondence: birgit.weinberger@uibk.ac.at
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indicate that CMV-seropositivity is associated with a
slight increase in overall mortality [11, 12]. It has been
demonstrated recently that CMV also affects B cell func-
tion. CMV-seropositivity is associated with decreased
switched memory B cells and in vitro activation of
activation-induced cytidine deaminase (AID), which are
predictors for successful influenza vaccination [13]. In
addition, CMV drives the expansion of CD56dimCD57
+NKG2C+ NK cells [14], skewing the NK cell repertoire
to more cytotoxic responses at the expense of cytokine-
driven functions. As a result, in vitro NK cell responses
to influenza and pertussis vaccine antigens are impaired
[15]. The impact of CMV-seropositivity or the level of
CMV-specific antibodies on immune responses after
vaccination is controversially discussed. Some studies re-
port that antibody responses to vaccines, e.g. against in-
fluenza, are lower in CMV-seropositive older individuals,
or in persons with high concentrations of CMV-specific
antibodies [16, 17]. In contrast, other studies did not ob-
serve an impact of CMV-infection on vaccine-induced
immune responses against influenza or Streptococcusle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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Fig. 1 Antibody concentrations and percentage of persons with
protective antibody concentrations. Diphtheria-specific antibody
concentrations were measured by ELISA prior to and 4 weeks after
vaccination. Two doses of diphtheria toxoid containing vaccines were
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impact of latent infection with CMV on the long-term
maintenance of vaccine-induced antibodies. We therefore
addressed this question using data from one of our previ-
ously published studies on the maintenance of tetanus-
and diphtheria-specific antibodies after vaccination of an
elderly cohort [20, 21]. We have demonstrated that recall
responses to diphtheria vaccination are frequently insuffi-
cient in elderly persons and that antibody concentrations
decline substantially within 5 years. Two hundred two
older adults (>60 years) received a single shot of tetanus
and diphtheria containing vaccine and antibody concen-
trations were measured before and 4 weeks after vaccin-
ation [20]. Five years later 87 persons of the original
cohort were willing to participate in a follow-up study and
received a second dose of tetanus and diphtheria vaccine.
Analysis of the long-term persistence of tetanus- and
diphtheria-specific antibodies was performed for this sub-
cohort [21]. We demonstrated that tetanus- and
diphtheria-specific antibody concentrations had dropped
to the level before the first vaccination within 5 years. As
tetanus-specific antibody concentrations were generally
higher, almost all participants were still protected. In con-
trast, 45% of our elderly cohort did not have protective
levels of diphtheria-specific antibodies 5 years after re-
vaccination (Table 1).
As protection against tetanus was generally high, we
focused on diphtheria in the current study and aimed to
evaluate the impact of latent infection with CMV on the
long-term maintenance of diphtheria-specific antibodies.
Antibody concentrations were similar for CMV-negative
and CMV-positive participants before the first vaccin-
ation. The vaccination history was very variable at this
time point probably masking a potential impact of latent
CMV-infection. Antibody concentrations increased to
the same extent in both groups after vaccination. Five
years later antibody concentrations had dropped to the
original levels in the CMV-positive group. In contrast,
antibody concentrations were still higher than baseline
for the CMV-negative group. The difference between
CMV-negative and CMV-positive participants was statis-
tically significant at this time point. After the secondTable 1 Number and percentage of persons with antibody
concentrations below the protective level
1st vaccination 2nd vaccination
day 0 day 28 day 0 day 28
Tetanus 10 (12%) 0 9 (10%) 0
Diphtheria 55 (65%) 9 (11%) 39 (45%) 6 (5%)
Number and percentage of persons (>60 years) with antibody concentrations
below the protective level (≤0.1 IU/ml) before and 4 weeks after vaccination
against tetanus and diphtheria. Data are shown for two vaccinations given at a
5-year interval. Data from [21]vaccination, antibody concentrations increased to similar
levels in both groups (Fig. 1a).
These differences in antibody concentrations were also
reflected in the percentage of persons with antibody
concentrations below the level considered to be protect-
ive (≤0.1 IU/ml). Five years after the first vaccination,
54% of the CMV-positive donors were not protected,
whereas only 33% of the CMV-negative donors had anti-
body concentrations below the protective level at this
time point. There were no differences in the levels of
protection between CMV-positive and CMV-negative
participants at the other time points (Fig. 1b). The differ-
ence in antibody concentrations observed prior to the
second vaccination is due to a more pronounced declineapplied in a 5-year interval. a Boxes show 25th and 75th percentiles,
the median value is indicated. Whiskers depict 5th and 95th
percentiles. Only donors, for whom data points were available at all 4
time points are included in the analysis. Differences between
CMV-negative and CMV-positive groups were calculated using
Mann-Whitney U test. Differences between day 0 (1st vaccination)
and day 0 (2nd vaccination) were calculated using Wilcoxon signed-
rank test. *p < 0.05; **p < 0.01; n.s.: not significant. b Percentage of
participants with antibody concentrations above (protected, solid
bar) or below (unprotected, dashed bar) levels considered to be
protective (0.1 IU/ml). The CMV-negative group is shown in white,
the CMV-positive group in gray. Differences in the percentage of
persons protected / unprotected were calculated using Pearson
Chi-square test. *p < 0.05; **p < 0.01; n.s.: not significant
Table 2 T cell and B cell subsets in CMV-negative and CMV-
positive individuals
CVM-negative CMV-positive p
mean ± SD mean ± SD
CD4+ naïve 63.0 ± 12.4 52.0 ± 15.5 0.029*
central memory 36.2 ± 12.5 38.5 ± 15.3 0.605
effector memory 0.6 ± 0.4 5.3 ± 4.2 <0.0001**
TEMRA 0.7 ± 0.6 4.7 ± 5.2 <0.0001**
CD8+ naïve 42.2 ± 16.2 28.9 ± 15.4 0.024*
central memory 25.4 ± 9.7 17.9 ± 14.0 0.005**
effector memory 8.9 ± 8.8 8.4 ± 7.3 0.939
TEMRA 24.5 ± 16.7 45.7 ± 17.5 0.001**
B cells IgM+ 19.5 ± 8.6 16.8 ± 5.6 0.286
IgD+ 67.7 ± 11.9 64.6 ± 12.5 0.564
IgG+ 11.2 ± 8.0 11.4 ± 4.4 0.323
memory IgG 8.3 ± 6.1 8.4 ± 3.6 0.485
exhausted 9.4 ± 2.6 11.2 ± 6.8 0.862
Percentage of naïve (CD45RO−CD28+), central memory (CD45RO+CD28+),
effector memory: (CD45RO+CD28−), and TEMRA (CD45RO−CD28−) cells within
CD3+CD4+ or CD3+CD8+ cells, respectively and of IgM+, IgD+, IgG+, memory
IgG (CD27+IgG+, and exhausted (IgD−CD27−) B cells within CD20+ cells. Shown
are mean values and standard deviation (SD) from 19 CMV-negative and 18
CMV-positive individuals. Differences between CMV-negative and CMV-positive
groups were calculated by Mann-Whitney-U test. *p < 0.05; **p < 0.01
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positive cohort (Fig. 2).
T and B cells subsets of 19 CMV-negative and 18
CMV-positive participants were analyzed by flow cytom-
etry at the time of the second vaccination. CMV-related
changes of T cell subsets, namely a decrease of naïve
and an increase of effector T cell subsets in CMV-
positive persons have been described [6, 8, 9] and could
be confirmed in our cohort. In contrast, no differences
of B cell subsets were observed (Table 2). Age-related
changes in the B cell compartment include a loss of
naïve B cells and an accumulation of highly differenti-
ated double negative (IgD−CD27−) cells [22], which were
also termed exhausted, and have been described to be
associated with lower responses to influenza vaccination
[23]. However, in accordance with our data, it has previ-
ously been reported that the influence of latent CMV in-
fection on the composition of B cell subsets is only
minimal [24], but that CMV infection might influence
the B cell repertoire [25].
summary, our data show that diphtheria-specific anti-
body concentrations decline faster in CMV-positive
compared to CMV-negative older adults leading to an
increased proportion of persons without protective anti-
body concentrations 5 years after booster vaccination
and endangering long-term protection. This finding
could be relevant for vaccination schedules. One pos-
sible reason for the faster decline of antibody concentra-
tions might be an impaired maintenance and/or survivalFig. 2 Decrease of diphtheria-specific antibody concentrations over
5 years. Depicted is the fold-reduction of diphtheria-specific antibodies
from 4 weeks after the first vaccination until immediately before the
second vaccination (5 years). Boxes show 25th and 75th percentiles, the
median value is indicated. Whiskers depict 5th and 95th percentiles. The
differences between CMV-negative and CMV-positive groups was
calculated using Mann-Whitney U test. *p < 0.05of long-lived plasma cells in the bone marrow. We have
previously reported a decrease of diphtheria-specific
plasma cells in the bone marrow with age [26], but the
CMV-status was not taken into consideration in this
small cohort. Recent data in our laboratory showed an
increase of inflammatory and oxidative stress parameters
in the bone marrow of older patients and at the same
time a decrease of IL-7 and a proliferation-inducing lig-
and (APRIL), which is a survival factor for plasma cells
[27]. The impact of latent CMV-infection on the bone
marrow microenvironment and the antigen-experienced
lymphocytes residing there is not yet known.
Materials and methods
Study cohort
For this study the 87 persons, who completed the 5-year
follow-up and received two vaccinations against tetanus
and diphtheria were included. In accordance with the
original study protocol persons with chronic viral infec-
tion (Human Immunodeficiency virus, Hepatitis B virus,
Hepatitis C virus), transplant recipients and patients
under immunosuppressive or chemotherapy were ex-
cluded. Routine laboratory parameters (liver and kidney
function, blood count) were determined. All participants
were shown to be in good health and there were no dif-
ferences between CMV-negative and CMV-positive per-
sons. Table 3 shows the patient characteristics for the
CMV-negative and the CMV-positive sub-cohort.
Table 3 Patient characteristics
CMV-negative CMV-positive p
n (%) 39 (44.8%) 48 (55.2%) -
age (median, range) 71 (66–92) 71 (67–89) 0.777a
female (%) 24 (61.5%) 25(50.0%) 0.282b
BMI (median, range) 24.8 (19.5–37.3) 26.1 (16–34.2) 0.155a
aMann-Whitney-U test or
bPearson Chi-square test was used to determine differences between CMV-
negative and CMV-positive groups
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Microtiter plates were coated with 1 μg/ml diphtheria
toxoid (Statens Serum Institute) and blocked with
0.01 M Glycin. Serum samples were tested in duplicates.
Peroxidase-labeled rabbit anti-human IgG (Chemicon/
Millipore) antibody was used as secondary antibody. IgG
antibodies were quantified in IU/ml using standard hu-
man anti-diphtheria serum (NIBSC). The detection limit
of the assays used was 0.01 IU/ml and values below the
limit of detection were set to 0.005 IU/ml. Antibody
concentrations above 0.1 IU/ml were considered as
protective.
Antibodies against Cytomegalovirus (CMV) were deter-
mined using a commercially available ELISA Kit (Siemens).
Reciprocal titers above 231 were considered positive.
Flow cytometry
PBMC were washed with PBS and stained with anti-
CD3-PE-Cy7 (Biolegend), anti-CD4-PerCP (BD Phar-
mingen), anti-CD8-PE (BD Pharmingen), anti CD28-
APC (Biolegend), anti CD45RO-FITC (BD Pharmingen),
anti-CD20-PerCP (Biolegend), anti-CD27-APC-Cy7(Bio-
legend) and anti-IgD-FITC (BD Pharmingen) antibodies
for 20 min, 4 °C in the dark. After washing with PBS,
cells were analyzed using a FACS Canto II cytometer
and FACSDiva software (BD).
Statistical analysis
Comparisons between two independent groups (CMV-
negative vs. CMV-positive) were calculated using Mann-
Whitney U test. Differences between paired samples (dif-
ferent time points) were calculated using Wilcoxon
signed-rank test. The distribution of categorical data
(e.g. protected/unprotected) was calculated using the
Pearson Chi-square test. p < 0.05 was considered signifi-
cant for all tests.
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